Survival by 100, 180, and 450 days after the first infusion of ABX-CBL
| . | ABX-CBL dose (mg/kg) . | All doses . | ||||
|---|---|---|---|---|---|---|
| 0.01 . | 0.1 . | 0.15 . | 0.24-150 . | 0.34-150 . | ||
| No. patients treated | 9 | 7 | 5 | 36 | 2 | 59 |
| No. (%) patients alive | ||||||
| at 100 days | 2 (22) | 4 (57) | 3 (60) | 18 (50) | 1 (50) | 28 (47) |
| at 180 days | 2 (22) | 3 (43) | 2 (40) | 18 (50) | 1 (50) | 26 (44) |
| at 450 days | 2 (22) | 3 (43) | 1 (20) | 10 (28) | 1 (50) | 17 (29) |
| . | ABX-CBL dose (mg/kg) . | All doses . | ||||
|---|---|---|---|---|---|---|
| 0.01 . | 0.1 . | 0.15 . | 0.24-150 . | 0.34-150 . | ||
| No. patients treated | 9 | 7 | 5 | 36 | 2 | 59 |
| No. (%) patients alive | ||||||
| at 100 days | 2 (22) | 4 (57) | 3 (60) | 18 (50) | 1 (50) | 28 (47) |
| at 180 days | 2 (22) | 3 (43) | 2 (40) | 18 (50) | 1 (50) | 26 (44) |
| at 450 days | 2 (22) | 3 (43) | 1 (20) | 10 (28) | 1 (50) | 17 (29) |
One of the patients originally assigned to receive ABX-CBL at 0.3 mg/kg had severe myalgia and received all subsequent doses at 0.2 mg/kg; the patient was, therefore, evaluated with the 0.2 mg/kg dose group for survival and response.